Urogen Pharma (NASDAQ:URGN) Stock Has Consensus Price Target of $52.38

Urogen Pharma (NASDAQ:URGN) has been given a consensus rating of “Moderate Buy” by the ten ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $52.38.

URGN has been the topic of a number of recent analyst reports. Guggenheim increased their price target on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $44.00 price objective on shares of Urogen Pharma in a research note on Wednesday, July 15th. TD Cowen upped their target price on shares of Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Jefferies Financial Group reaffirmed a “buy” rating and set a $56.00 target price on shares of Urogen Pharma in a report on Thursday, September 10th. Finally, UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a research note on Thursday, July 9th.

Insider Transactions at Urogen Pharma

In related news, General Counsel Jason Smith sold 1,519 shares of Urogen Pharma stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total transaction of $64,618.26. Following the completion of the sale, the general counsel owned 53,141 shares of the company’s stock, valued at approximately $2,260,618.14. This trade represents a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Schoenberg sold 60,677 shares of Urogen Pharma stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $47.05, for a total value of $2,854,852.85. Following the sale, the insider directly owned 59,086 shares of the company’s stock, valued at $2,779,996.30. This represents a 50.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 65,269 shares of company stock valued at $3,037,646. 4.80% of the stock is currently owned by company insiders.

Institutional Trading of Urogen Pharma

A number of large investors have recently modified their holdings of the business. Opaleye Management Inc. grew its stake in Urogen Pharma by 0.7% in the 2nd quarter. Opaleye Management Inc. now owns 1,439,996 shares of the company’s stock worth $52,992,000 after buying an additional 9,996 shares in the last quarter. Engineers Gate Manager LP bought a new stake in shares of Urogen Pharma during the 2nd quarter worth $603,000. Squarepoint Ops LLC bought a new stake in shares of Urogen Pharma during the 2nd quarter worth $431,000. Wellington Management Group LLP lifted its holdings in shares of Urogen Pharma by 15.1% during the 2nd quarter. Wellington Management Group LLP now owns 115,362 shares of the company’s stock worth $4,245,000 after acquiring an additional 15,147 shares during the last quarter. Finally, Palo Alto Investors LP purchased a new position in Urogen Pharma in the second quarter worth $901,600. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Price Performance

NASDAQ URGN opened at $34.56 on Monday. The company’s 50 day moving average is $43.16 and its 200-day moving average is $35.26. Urogen Pharma has a 12-month low of $16.36 and a 12-month high of $50.81.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million for the quarter, compared to analyst estimates of $63.55 million. On average, equities analysts expect that Urogen Pharma will post -0.20 EPS for the current year.

About Urogen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company’s platform is based on RTGel, a proprietary reverse-thermal hydrogel designed to retain medicines in the urinary tract and provide localized treatment while limiting systemic exposure.

UroGen’s lead commercial product is JELMYTO (mitomycin), a gel-based therapy approved by the U.S. Food and Drug Administration for the primary chemoablation of low-grade upper tract urothelial cancer in adults.